$6.6 million 4th Qtr 2017 Tight Estimate
You are right, but the big question is why on earth MNK can sell only 1-2% compared to Accord and Lupin sales even though they got approval together?
This leaves much to gain to MNK.
If MNK got 1000% growth right now, it still would sell only 10% compared to Accord and 20% compared to Lupin.
Well - the numbers are prescription counts, not dollars, but anyway. I suppose you got the point.